Speed to Market: Where is the evidence for EU oncology approvals?

Recent BMJ review looks at the data on oncology drugs approved in the EU from 2009-2013 to assess the overall survival and quality of life benefits. The analysis sparks the debate on whether newer regulatory pathways which attempt to get potentially life saving drugs into the hands of oncologists is at the cost of approving drugs with minimal benefit.

Click on image above to go to BMJ article and listen to podcast.